SEARCH:
Sign in | Join | Help
search Mercola.com
 
FREE Subscription 
The World’s Most Popular Natural Health Newsletter
Over Dose: The Case Against the Drug Companies
Posted by: Dr. Mercola
February 06 2002 | 1,033 views

References for Part 1 of Over Dose: The Case Against the Drug Companies

1. Wernicke, JF, Dunlop, SR, Dornseif, BE, Bosomworth, JC, Humbert, M. Low-dose fluoxetine therapy for depression. Psychopharmacology Bulletin, 1988; 24(1):183-188.

2. Louie, AK, Lewis, TB, Lannon, MD. Use of low-dose fluoxetine in major depression and panic disorder. Journal of Clinical Psychiatry, 1993;54(1):435-438.

3. Lazarou J; Pomeranz BH; Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta?analysis of prospective studies [see comments]. JAMA, 1998 Apr 15, 279(15):1200?5.

4. Ibid.

5. Gilman, AG, Rall, TW, Nies, AS, Taylor, P. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: Pergammon Press, 1990 and 1996.

6. Kolata, G. (New York Times News Service). Who cares when our drugs fail? San Diego Union-Tribune, Weds., Oct. 15, 1997: E-1,5.

7. Melmon, K.L., Morrelli, H.F., Hoffman, B.B., & Nierenberg, D.W. Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics. (3rd Edition). New York: McGraw-Hill, Inc., 1993.

8. Moore TJ; Psaty BM; Furberg CD. Time to act on drug safety. JAMA, 1998 May 20, 279(19):1571?3.

9. Cullen DJ; Bates DW; Small SD; Cooper JB; Nemeskal AR; Leape LL. The incident reporting system does not detect adverse drug events: a problem for quality improvement. Joint Commission Journal on Quality Improvement, 1995 Oct, 21(10):541?8.

10. Bates DW. Drugs and adverse drug reactions: how worried should we be? JAMA, 1998 Apr 15, 279(15):1216?7.

11. Dickinson, JG. FDA seeks to double effort on confusing drug names. Dickinson's FDA Review, March 2000; 7(3):13-14.

12. Marks L. "Not just a statistic": the history of USA and UK policy over thrombotic disease and the oral contraceptive pill, 1960s?1970s. Social Science and Medicine, 1999 Nov, 49(9):1139?55.
[12A. Snider, S. The Pill: 30 Years of Safety Concerns. U.S. Food and Drug Administration, Dec. 1990; FDA Website.]

13. Van Hoften C; Burger H; Peeters PH; Grobbee DE; Van Noord PA; Leufkens HG. Long?term oral contraceptive use increases breast cancer risk in women over 55 years of age: the DOM cohort. International Journal of Cancer, 2000;87(4):591?4.

14. Burke, W. Oral Contraceptives and Breast Cancer. JAMA, Oct. 11, 2000; 284:1837-38.

15. Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstetrics and Gynecology, 1995 May, 85(5 Pt 1):793?801.

16. Bagshaw, S. The Combined Oral Contraceptive. Drug Safety, 1995; 12:91-96.

17. Ettinger B. Personal perspective on low?dosage estrogen therapy for postmenopausal women. Menopause, 1999; 6(3):273?6.

18. Weinstein L. Efficacy of a continuous estrogen?progestin regimen in the menopausal patient. Obstetrics and Gynecology, 1987;69(6):929?32.

19. Greendale GA, Reboussin BA, Hogan P, Barnabei VM, Shumaker S, Johnson S, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstetrics and Gynecology, 1998;92(6):982?8.

20. Ettinger B. op cit.

21. American Society of Hospital Pharmacists. American Hospital Formulary Service, Drug Information 1999. Gerald K. McEvoy, Editor. Bethesda: 1999.

22. American Medical Association. AMA Drug Evaluations, Annual 1993. Chicago: American Medical Association, 1993.

23. Lindsay R; Hart DM; Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstetrics and Gynecology, 1984;63(6):759?63.

24. Ettinger B. A practical guide to preventing osteoporosis. Western Journal of Medicine, 1988;149(6):691?5.

25. Schairer C; Lubin J; Troisi R; Sturgeon S; Brinton L; Hoover R. Menopausal estrogen and estrogen?progestin replacement therapy and breast cancer risk. Jama, 2000 Jan 26, 283(4):485?91.

26. Persson I; Weiderpass E; Bergkvist L; Bergstrom R; Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen?progestin replacement. Cancer Causes and Control, 1999 Aug, 10(4):253?60.

27. Peck, C., Barr, W., Benet, L., Collins, J., Desjardins, R., Furst, D., et al. Opportunities for integrating of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Journal of Clinical Pharmacology, 1994; 34:111-9.

28. Peck CC. Drug development: improving the process. Food Drug Law Journal, 1997; 52:163-7.

29. Woosley, RL. Drug Labeling Revisions -- Guaranteed to Fail? JAMA, Dec. 20, 2000; 284(23):3047-49.

30. Sussman, N. More Questions Than Answers. Primary Psychiatry, 2000; 7:6.

31. Angell, M. The Pharmaceutical Industry -- To Whom Is It Accountable? New England Journal of Medicine, 2000; 342:1902-4.

32. Melmon et al., op. cit.

33. Bowman, L. 51% Of U.S. Adults Take 2 Pills or More a Day, Survey Reports (Scripps Howard News Service). San Diego Union-Tribune, Weds., Jan. 17, 2001:A8.

34. Cullen et al., op. cit.

35. Gilman et al., op. cit.

36. Cohen JS; Insel PA. The Physicians' Desk Reference. Problems and possible improvements. Archives of Internal Medicine, 1996; 156(13):1375?80.

37. Cohen, JS. Adverse drug effects, compliance, and the initial doses of antihypertensive drugs recommended by the Joint National Community vs. the Physicians' Desk Reference. Archives of Internal Medicine, 2001;161:880-85.

38. Cohen, JS. Dose Discrepancies between the Physicians' Desk Reference and the Medical Literature, and Their Possible Role in the High Incidence of Dose-Related Adverse Drug Events. Archives of Internal Medicine, April 9, 2001: Scheduled for Publication.

39. Cohen, J.S. Ways To Minimize Adverse Drug Reactions: Individualized Doses and Common Sense Are Key. Postgraduate Medicine, Sept. 1999; 106: 163-72.

40. Cohen, JS. Adverse Drug Reactions: Effective Low-Dose Therapies for Older Patients. Geriatrics, Feb. 2000; 55(2):54-64.

41. Cohen, JS. Comparison of FDA Reports of Patient Deaths Associated with Sildenafil (Viagra) and with Injectable Alprostadil. Annals of Pharmacotherapy, March 2001;35:285-88.

42. Cohen, JS. Is the Product Information on Sildenafil (Viagra) Adequate to Facilitate Optimal Therapeutics and to Minimize Adverse Events? Annals of Pharmacotherapy, March 2001;35:337-42.

43. Cohen, JS. Should Patients Be Given a Low Test Dose of Viagra Initially? Drug Safety, July 2000; 23:1-10.

44. Rennie, D. Fair Conduct and Fair Reporting of Clinical Trials. JAMA, 1999; 282:1766-68.

45. Bodenheimer, T. Uneasy Alliance -- Clinical Investigators and the Pharmaceutical Industry. New England Journal of Medicine, 2000; 342:1539-44.

46. Huston, P. Redundancy, Disaggregation, and the Integrity of Medical Research. Lancet, 1996, Apr. 13;347(9007):1024-26.

47. Bodenheimer, op. cit.

48. Hotz, RL. Secrecy is often the price of medical research funding. Los Angeles Times, May 18, 1999; A-2, 21.

49. Angell, M. Is Academic Medicine for Sale? New England Journal of Medicine, May 18, 2000; 342:1516-18:

50. Ibid.

51. Sussman, op. cit.

52. Wazana, A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA, 2000; 283(3):373?80.

53. Physicians' Desk Reference, 54th Edition. Montvale, N.J.: Medical Economics Company, 2000.

Return to Part 1 of Over Dose: The Case Against the Drug Companies






 
 
 
© Copyright 2009 Dr. Joseph Mercola. All Rights Reserved. If you want to use this article on your site please click here. This content may be copied in full, with copyright, contact, creation and information intact, without specific permission, when used only in a not-for-profit format. If any other use is desired, permission in writing from Dr. Mercola is required.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. If you are pregnant, nursing, taking medication, or have a medical condition, consult your physician before using this product.